Abstract
The recent elucidation both of the mechanisms involved in pancreatic cancer carcinogenesis and the related molecular events, has led to several distinct therapeutic advances, including many novel target agents, such as monoclonal antibodies against EGFR, EGFR-tyrosine kinase inhibitors, monoclonal antibody against VEGF, farnesyl transferase inhibitors, matrix metalloproteinase inhibitors, COX 2 inhibitors, and the development of gene therapy to target pancreatic cancer. This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches.
MeSH terms
-
Cyclooxygenase 2 Inhibitors / therapeutic use
-
Disease Progression
-
Drug Delivery Systems
-
ErbB Receptors / antagonists & inhibitors
-
Farnesyltranstransferase / antagonists & inhibitors
-
Gene Targeting
-
Humans
-
Metalloproteases / antagonists & inhibitors
-
NF-kappa B / antagonists & inhibitors
-
Pancreatic Neoplasms / enzymology
-
Pancreatic Neoplasms / genetics
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / therapy*
-
Protease Inhibitors / therapeutic use
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Cyclooxygenase 2 Inhibitors
-
NF-kappa B
-
Protease Inhibitors
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Farnesyltranstransferase
-
EGFR protein, human
-
ErbB Receptors
-
Metalloproteases